Annual EBITDA
-$269.00 M
+$22.00 M+7.56%
December 31, 2024
Summary
- As of March 6, 2025, RCUS annual EBITDA is -$269.00 million, with the most recent change of +$22.00 million (+7.56%) on December 31, 2024.
- During the last 3 years, RCUS annual EBITDA has fallen by -$328.00 million (-555.93%).
- RCUS annual EBITDA is now -555.93% below its all-time high of $59.00 million, reached on December 31, 2021.
Performance
RCUS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$89.00 M
$0.000.00%
December 31, 2024
Summary
- As of March 6, 2025, RCUS quarterly EBITDA is -$89.00 million, unchanged on December 31, 2024.
- Over the past year, RCUS quarterly EBITDA has stayed the same.
- RCUS quarterly EBITDA is now -131.45% below its all-time high of $282.95 million, reached on December 31, 2021.
Performance
RCUS Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$269.00 M
-$12.00 M-4.67%
December 31, 2024
Summary
- As of March 6, 2025, RCUS TTM EBITDA is -$269.00 million, with the most recent change of -$12.00 million (-4.67%) on December 31, 2024.
- Over the past year, RCUS TTM EBITDA has stayed the same.
- RCUS TTM EBITDA is now -399.04% below its all-time high of $89.95 million, reached on September 30, 2022.
Performance
RCUS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
RCUS EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +7.6% | 0.0% | 0.0% |
| 3 y3 years | -555.9% | -131.4% | -555.9% |
| 5 y5 years | -231.6% | -602.3% | -231.6% |
RCUS EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -555.9% | +7.6% | -131.4% | +2.2% | -399.0% | +7.6% |
| 5 y | 5-year | -555.9% | +7.6% | -131.4% | +2.2% | -399.0% | +7.6% |
| alltime | all time | -555.9% | +7.6% | -131.4% | +2.2% | -399.0% | +7.6% |
Arcus Biosciences EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$269.00 M(-7.6%) | -$89.00 M(0.0%) | -$269.00 M(+4.7%) |
| Sep 2024 | - | -$89.00 M(-2.2%) | -$257.00 M(+9.4%) |
| Jun 2024 | - | -$91.00 M(<-9900.0%) | -$235.00 M(+8.8%) |
| Mar 2024 | - | $0.00(-100.0%) | -$216.00 M(-25.8%) |
| Dec 2023 | -$291.00 M(+12.8%) | -$77.00 M(+14.9%) | -$291.00 M(+4.3%) |
| Sep 2023 | - | -$67.00 M(-6.9%) | -$279.00 M(+1.5%) |
| Jun 2023 | - | -$72.00 M(-4.0%) | -$275.00 M(+3.0%) |
| Mar 2023 | - | -$75.00 M(+15.4%) | -$267.00 M(+3.5%) |
| Dec 2022 | -$258.00 M(-537.3%) | -$65.00 M(+3.2%) | -$258.00 M(-386.8%) |
| Sep 2022 | - | -$63.00 M(-1.6%) | $89.95 M(+18.5%) |
| Jun 2022 | - | -$64.00 M(-3.0%) | $75.94 M(+17.2%) |
| Mar 2022 | - | -$66.00 M(-123.3%) | $64.79 M(+9.8%) |
| Dec 2021 | $59.00 M(-149.2%) | $282.95 M(-467.4%) | $59.00 M(-121.5%) |
| Sep 2021 | - | -$77.01 M(+2.5%) | -$274.65 M(+40.8%) |
| Jun 2021 | - | -$75.15 M(+4.7%) | -$195.09 M(+18.7%) |
| Mar 2021 | - | -$71.79 M(+41.6%) | -$164.38 M(+37.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2020 | -$120.00 M(+47.9%) | -$50.70 M(-2086.7%) | -$120.00 M(+46.4%) |
| Sep 2020 | - | $2.55 M(-105.7%) | -$81.97 M(-23.3%) |
| Jun 2020 | - | -$44.44 M(+62.1%) | -$106.89 M(+17.8%) |
| Mar 2020 | - | -$27.41 M(+116.3%) | -$90.73 M(+11.8%) |
| Dec 2019 | -$81.13 M(+58.5%) | -$12.67 M(-43.3%) | -$81.13 M(+0.2%) |
| Sep 2019 | - | -$22.36 M(-20.9%) | -$81.00 M(+16.0%) |
| Jun 2019 | - | -$28.28 M(+58.7%) | -$69.81 M(+23.5%) |
| Mar 2019 | - | -$17.82 M(+42.1%) | -$56.51 M(+10.4%) |
| Dec 2018 | -$51.20 M(+0.7%) | -$12.54 M(+12.2%) | -$51.20 M(-0.1%) |
| Sep 2018 | - | -$11.17 M(-25.4%) | -$51.24 M(-18.0%) |
| Jun 2018 | - | -$14.98 M(+19.8%) | -$62.47 M(+10.5%) |
| Mar 2018 | - | -$12.50 M(-0.6%) | -$56.52 M(+11.2%) |
| Dec 2017 | -$50.83 M(+201.3%) | -$12.58 M(-43.9%) | -$50.83 M(+32.9%) |
| Sep 2017 | - | -$22.40 M(+147.9%) | -$38.25 M(+141.3%) |
| Jun 2017 | - | -$9.04 M(+32.6%) | -$15.85 M(+132.6%) |
| Mar 2017 | - | -$6.81 M | -$6.81 M |
| Dec 2016 | -$16.87 M | - | - |
FAQ
- What is Arcus Biosciences annual EBITDA?
- What is the all time high annual EBITDA for Arcus Biosciences?
- What is Arcus Biosciences annual EBITDA year-on-year change?
- What is Arcus Biosciences quarterly EBITDA?
- What is the all time high quarterly EBITDA for Arcus Biosciences?
- What is Arcus Biosciences quarterly EBITDA year-on-year change?
- What is Arcus Biosciences TTM EBITDA?
- What is the all time high TTM EBITDA for Arcus Biosciences?
- What is Arcus Biosciences TTM EBITDA year-on-year change?
What is Arcus Biosciences annual EBITDA?
The current annual EBITDA of RCUS is -$269.00 M
What is the all time high annual EBITDA for Arcus Biosciences?
Arcus Biosciences all-time high annual EBITDA is $59.00 M
What is Arcus Biosciences annual EBITDA year-on-year change?
Over the past year, RCUS annual EBITDA has changed by +$22.00 M (+7.56%)
What is Arcus Biosciences quarterly EBITDA?
The current quarterly EBITDA of RCUS is -$89.00 M
What is the all time high quarterly EBITDA for Arcus Biosciences?
Arcus Biosciences all-time high quarterly EBITDA is $282.95 M
What is Arcus Biosciences quarterly EBITDA year-on-year change?
Over the past year, RCUS quarterly EBITDA has changed by $0.00 (0.00%)
What is Arcus Biosciences TTM EBITDA?
The current TTM EBITDA of RCUS is -$269.00 M
What is the all time high TTM EBITDA for Arcus Biosciences?
Arcus Biosciences all-time high TTM EBITDA is $89.95 M
What is Arcus Biosciences TTM EBITDA year-on-year change?
Over the past year, RCUS TTM EBITDA has changed by $0.00 (0.00%)